Turtle Creek Wealth Advisors LLC Sells 11,390 Shares of Zoetis Inc. (NYSE:ZTS)

Turtle Creek Wealth Advisors LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,131 shares of the company's stock after selling 11,390 shares during the quarter. Turtle Creek Wealth Advisors LLC's holdings in Zoetis were worth $3,117,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. State Street Corp grew its position in shares of Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company's stock worth $3,864,488,000 after buying an additional 95,856 shares during the period. Geode Capital Management LLC raised its holdings in shares of Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the period. Mizuho Securities USA LLC boosted its position in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Zoetis by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock valued at $761,221,000 after buying an additional 194,542 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock valued at $569,834,000 after buying an additional 279,092 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

ZTS stock traded up $0.30 during midday trading on Tuesday, hitting $172.24. The company's stock had a trading volume of 2,696,086 shares, compared to its average volume of 2,684,732. The stock has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock's 50-day moving average price is $169.48 and its 200 day moving average price is $179.39. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.36 EPS. On average, equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. This is a positive change from Zoetis's previous quarterly dividend of $0.43. Zoetis's dividend payout ratio (DPR) is presently 37.59%.

Analyst Ratings Changes

Several brokerages have issued reports on ZTS. Morgan Stanley cut their price target on Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 target price for the company. Finally, UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.